Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and adjuvant Iparomlimab/Tuvonralimab for MSI-H/dMMR locally advanced gastric adenocarcinoma (Phase II, single-arm)
ChiCTR2600125006Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab + tuvonralimab in gastric adenocarcinoma, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Pathological Complete Response (pCR) Rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600125006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125006.